Head-To-Head Comparison: ALT5 Sigma (AIFC) vs. The Competition

ALT5 Sigma (NASDAQ:AIFC) is one of 345 publicly-traded companies in the “Financial Services” industry, but how does it weigh in compared to its peers? We will compare ALT5 Sigma to related businesses based on the strength of its risk, dividends, institutional ownership, earnings, profitability, analyst recommendations and valuation.

Volatility and Risk

ALT5 Sigma has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, ALT5 Sigma’s peers have a beta of 2.26, indicating that their average stock price is 126% more volatile than the S&P 500.

Insider & Institutional Ownership

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by company insiders. Comparatively, 21.8% of shares of all “Financial Services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for ALT5 Sigma and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
ALT5 Sigma Competitors	1889	6807	11500	414	2.51

As a group, “Financial Services” companies have a potential upside of 4.09%. Given ALT5 Sigma’s peers stronger consensus rating and higher probable upside, analysts plainly believe ALT5 Sigma has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares ALT5 Sigma and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ALT5 Sigma	$24.84 million	-$344.51 million	1.25
ALT5 Sigma Competitors	$11.23 billion	$1.07 billion	10.49

ALT5 Sigma’s peers have higher revenue and earnings than ALT5 Sigma. ALT5 Sigma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares ALT5 Sigma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-4,021.65%	-51.87%	-48.30%
ALT5 Sigma Competitors	-405.59%	-21.92%	-5.67%

Summary

ALT5 Sigma peers beat ALT5 Sigma on 13 of the 13 factors compared.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.